Announcement Summary

Entity name

ANATARA LIFESCIENCES LTD

Announcement Type

New announcement

Date of this announcement

Wednesday October 21, 2020

The Proposed issue is:

☑ An offer of securities under a securities purchase plan

Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan

		Maximum Number of
ASX +security code	+Security description	+securities to be issued

ANR ORDINARY FULLY PAID 5,000,000

+Record date

Tuesday October 20, 2020

Offer closing date

Wednesday November 11, 2020

+Issue date

Wednesday November 18, 2020

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

ANATARA LIFESCIENCES LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

Registration Number

ACN

145239872

1.3 ASX issuer code

ANR

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

Wednesday October 21, 2020

1.6 The Proposed issue is:

☑ An offer of +securities under a +securities purchase plan

Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 - Are any of the following approvals required for the offer of +securities under the +securities purchase plan issue to be unconditional?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

☑ No

Part 4B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

ANR: ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities?

☑ No

Details of +securities proposed to be issued

ASX +security code and description

ANR: ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

5,000,000

Proposed issue of securities

Describe the minimum subscription condition

Minimum of \$2,500

\$750,000 divided by the SPP Offer price.

The SPP Offer price will be the 80% of the 5 day VWAP over the last 5 days on which sales in ANR Shares were recorded before the day on which the issue was made, subject to the SPP Offer price being no less than \$0.15

Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?

☑ Yes

Describe the maximum subscription condition

Maximum of \$30,000

Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?

Yes

Is the minimum acceptance unit based or dollar based?

☑ Dollar based (\$)

Please enter the minimum acceptance value

\$ 2,500

Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?

Yes

Is the maximum acceptance unit based or dollar based?

☑ Dollar based (\$)

Please enter the maximum acceptance value

\$ 30,000

Describe all the applicable parcels available for this offer in number of securities or dollar value

\$2,500, \$5,000, \$7,500, \$10,000, \$12, 500, \$15,000, \$20,000, \$22,500, \$27,500 or \$30,000

Offer price details

Has the offer price been determined?

☑ No

How and when will the offer price be determined?

\$750,000 divided by the SPP Offer price.

The SPP Offer price will be the 80% of the 5 day VWAP over the last 5 days on which sales in ANR Shares were recorded before the day on which the issue was made, subject to the SPP Offer price being no less than \$0.15.

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed?

Yes

Proposed issue of securities

Describe the scale back arrangements

If demand exceeds A\$750,000, the Company may scale back applications under the SPP.

It is the intention of the Board to scale-back on a pro-rata basis using a consistent percentage across all applications.

Any scale back decisions will be made by the Board in its absolute discretion and the decision of the Board is final.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

(% Yes

Part 4C - Timetable

4C.1 Date of announcement of +security purchase plan

Wednesday October 21, 2020

4C.2 +Record date

Tuesday October 20, 2020

4C.3 Date on which offer documents will be made available to investors

Wednesday October 28, 2020

4C.4 Offer open date

Wednesday October 28, 2020

4C.5 Offer closing date

Wednesday November 11, 2020

4C.6 Announcement of results

Monday November 16, 2020

4C.7 +Issue date

Wednesday November 18, 2020

Part 4D - Listing Rule requirements

Part 4E - Fees and expenses

0	E.1 Will there be a lead manager or broker to the proposed offer? No
	E.2 Is the proposed offer to be underwritten? No
	E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a andling fee or commission?
©	No The Control of the
4!	E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed o
Γ.	
	None
4F	- Further Information F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue
4F	- Further Information F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue
4F 4I	- Further Information F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue The funds raised from the issue of the issue of the SPP Shares will be used for clinical trials as well as general work
4F	- Further Information F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue The funds raised from the issue of the issue of the SPP Shares will be used for clinical trials as well as general work capital requirements. F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?
4F 4I 4I 6	- Further Information F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue The funds raised from the issue of the issue of the SPP Shares will be used for clinical trials as well as general work capital requirements. F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?
4F 4I 4I 6	- Further Information F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue The funds raised from the issue of the issue of the SPP Shares will be used for clinical trials as well as general work capital requirements. F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? No F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer